Ceva Animal Health has announced the strategic acquisition of Scout Bio, a pioneer in biotechnology focused on cutting-edge therapies for pets.
The move represents a significant leap in innovation for Ceva, unlocking access to key advancements including a pipeline of monoclonal antibodies and gene therapy developments to address chronic diseases in pets.
While maintaining strong positions and continuing to develop biological and preventive medicine for all species, with this strategic acquisition Ceva aims to boost its global biotechnology activities, drawing on Scout Bio’s heritage but more importantly, fostering a future characterised by the acceleration of biotherapeutic innovation.
Scout Bio, renowned for its commitment to innovation, has been at the forefront of developing groundbreaking biotherapeutic products.
Mark Heffernan, former CEO of Scout Bio, who has joined Ceva as senior vice president of biotherapeutics and chief executive of Ceva Biotechnology Campus (Philadelphia), said: “
expressed his enthusiasm by declaring:
“With this acquisition, Ceva is ready to write a new chapter. The strength of the Group, which is one of the leaders in animal health, will propel our existing and future initiatives to new heights.
“Ceva has not only recognised our team’s delivery on innovation, but also our commitment to execution of quality clinical studies. With the power of Ceva, we will be able to accelerate biotherapeutic innovation for the well-being of pets and the happiness of their owners.”
